Division of Acute Care Surgery, Department of Surgery, University of Michigan Health System, 1500 East Medical Center Drive, 1C340A-UH, SPC 5033, Ann Arbor, MI 48109-5033, USA.
Crit Care Clin. 2011 Jul;27(3):525-59. doi: 10.1016/j.ccc.2011.04.005.
This article examines exogenous lung surfactant replacement therapy and its usefulness in mitigating clinical acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS). Surfactant therapy is beneficial in term infants with pneumonia and meconium aspiration lung injury, and in children up to age 21 years with direct pulmonary forms of ALI/ARDS. However, extension of exogenous surfactant therapy to adults with respiratory failure and clinical ALI/ARDS remains a challenge. This article reviews clinical studies of surfactant therapy in pediatric and adult patients with ALI/ARDS, focusing on its potential advantages in patients with direct pulmonary forms of these syndromes.
本文探讨了外源性肺表面活性剂替代疗法及其在减轻临床急性肺损伤 (ALI) 和急性呼吸窘迫综合征 (ARDS) 方面的作用。表面活性剂疗法对患有肺炎和胎粪吸入性肺损伤的早产儿以及年龄在 21 岁以下的直接肺部 ALI/ARDS 患儿有益。然而，将外源性表面活性剂疗法扩展到患有呼吸衰竭和临床 ALI/ARDS 的成人仍然是一个挑战。本文回顾了外源性肺表面活性剂在儿科和成人 ALI/ARDS 患者中的临床研究，重点关注其在这些综合征的直接肺部形式患者中的潜在优势。
